The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review
Molecular and Cellular Neuroscience · 2026
DOI: 10.1016/j.mcn.2026.104091 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Molecular and Cellular Neuroscience, 2026. Verfasst von Eve Corcoran und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Anglia Ruskin University, Bishop Hall Road, Chelmsford, CM1 1SQ, UK. Hauptthemen laut MEDLINE: Alzheimer Disease, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
BACKGROUND: The incidence of Alzheimer's disease (AD) is increasing globally but there are limited effective therapies available. Recently, evidence has demonstrated a role of GLP-1 receptor (GLP-1R) agonists, commonly used in the treatment of type 2 diabetes, may have therapeutic potential in AD. GLP-1R agonists have exhibited their neuroprotective role by targeting tau hyperphosphorylation and the accumulation of beta-amyloid (Aβ) plaques. This systematic review aims to evaluate the effectiveness of liraglutide, semaglutide, exenatide and dulaglutide on AD pathology with a focus on the key biomarkers: hyperphosphorylated tau and Aβ. METHODS: A systematic literature search was conducted using PubMed, Embase and Cochrane Library. Inclusion criteria involved pre-clinical and clinical studies investigating the effects of GLP-1 agonists dulaglutide, liraglutide, semaglutide or exenatide on Aβ and tau pathology. Randomised and non-randomised studies were included. Exclusion criteria involved studies evaluating GLP-1R agonists other than those specified. RESULTS: This review examined thirty preclinical studies investigating the effects of four GLP-1 receptor agonists on Alzheimer's disease pathology, particularly Aβ plaque accumulation and tau hyperphosphorylation. Most studies focused on liraglutide, which consistently reduced both Aβ and tau pathology in animal and cell models. Dulaglutide, although studied less frequently, consistently reduced tau phosphorylation and Aβ accumulation in mouse models while also improving cognitive outcomes. Semaglutide also showed largely positive effects with four studies reporting reduced Aβ or tau pathology, though one study reported no benefit. Two clinical studies were also reviewed. A phase II trial of Exenatide showed reduced plasma Aβ42 in extracellular vesicles but not cognitive benefit. A smaller liraglutide trial demonstrated no reduction in Aβ burden or cognitive change though it preserved brain glucose metabolism. An EXSCEL trial showed significant changes in systemic inflammatory markers. While pre-clinical data has been encouraging, clinical evidence remains limited. CONCLUSIONS: There is consistent preclinical evidence that GLP-1R agonists are effective in reducing Aβ levels and hyperphosphorylated tau. While the neuroprotective effect in preclinical studies is clear, clinical findings have so far failed to demonstrate an arresting effect on cognitive. REGISTRATION: PROSPERO CRD420251029748.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Anglia Ruskin University, Bishop Hall Road, Chelmsford, CM1 1SQ, UK.
- School of Medicine, Anglia Ruskin University, Bishop Hall Road, Chelmsford, CM1 1SQ, UK. Electronic address: simon.cork@aru.ac.uk.
Zitieren
APA
Corcoran, E., Kettlety, M., Mogul, U., Azah, J. N., & Cork, S. C. (2026). The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review. Molecular and Cellular Neuroscience. https://doi.org/10.1016/j.mcn.2026.104091
Vancouver
Corcoran E, Kettlety M, Mogul U, Azah JN, Cork SC. The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review. Molecular and Cellular Neuroscience. 2026. doi:10.1016/j.mcn.2026.104091
BibTeX
@article{Corcoran2026,
author = {Corcoran, Eve and Kettlety, Michael and Mogul, Urwa and Azah, Jennifer Ndiforngwah and Cork, Simon C},
title = {The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review},
journal = {Molecular and Cellular Neuroscience},
year = {2026},
doi = {10.1016/j.mcn.2026.104091}
}
EUVIMED